Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Feb;45(1):51-64.
doi: 10.1080/1040841X.2018.1538934. Epub 2018 Dec 6.

Underscoring interstrain variability and the impact of growth conditions on associated antimicrobial susceptibilities in preclinical testing of novel antimicrobial drugs

Affiliations
Review

Underscoring interstrain variability and the impact of growth conditions on associated antimicrobial susceptibilities in preclinical testing of novel antimicrobial drugs

David A Sanchez et al. Crit Rev Microbiol. 2019 Feb.

Abstract

In the era of multidrug resistant (MDR) organisms, reliable efficacy testing of novel antimicrobials during developmental stages is of paramount concern prior to introduction in clinical trials. Unfortunately, interstrain variability is often underappreciated when appraising the efficacy of innovative antimicrobials as preclinical testing of a limited number of standardized strains in unvarying conditions does not account for the vastness and potential for hyperdiversity among and within microbial populations. In this review, the importance of accounting for interstrain variability's potential to impact breadth of novel drug efficacy evaluation in the early stages of drug development will be discussed. Additionally, testing under varying microenvironmental conditions that may influence drug efficacy will be discussed. Biofilm growth, the influence of polymicrobial growth, mechanisms of antimicrobial resistance, pH, anaerobic conditions, and other virulence factors are some of critical issues that require more attention and standardization during preclinical drug efficacy evaluation. Furthermore, potential solutions for addressing this issue in pre-clinical antimicrobial development are proposed via centralization of microbial characterization and drug target databases, testing of a large number of clinical strains, inclusion of mutator strains in testing and the use of growth parameter mathematical models for testing.

Keywords: Antimicrobials; infection; resistance; strains; variability.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Alnuaimi AD, O’Brien-Simpson NM, Reynolds EC, McCullough MJ. 2013. Clinical isolates and laboratory reference Candida species and strains have varying abilities to form biofilms. FEMS Yeast Res 13(7):689–699. - PubMed
    1. Aminov R. History of antimicrobial drug discovery - Major classes and health impact. Biochem Pharmacol. eng. 2016. - PubMed
    1. Andersson DI, Hughes D. 2010. Antibiotic resistance and its cost: is it possible to reverse resistance? Nat Rev Microbiol 8(4):260–271. eng. - PubMed
    1. Andrei S, Valeanu L, Chirvasuta R, Stefan MG. 2018. New FDA Approved Antibacterial Drugs: 2015–2017. Discoveries 6:e81. - PMC - PubMed
    1. Balaei-Gajan E, Shirmohammadi A, Abashov R, Agazadeh M, Faramarzie M. 2010. Detection of enterococcus faecalis in subgingival biofilm of patients with chronic refractory periodontitis. Med Oral Patol Oral Cir Bucal 15(4):e667–670. - PubMed

MeSH terms

Substances